Combinations of cannabinoids and n-acylethanolamines

Abstract

The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

1 .- 48 . (canceled) 
     
     
         49 . A dosage unit comprising a therapeutically-effective amount of a pharmaceutical composition comprising at least one phyto-cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof in a molar ratio of the phyto-cannabinoid and N-acylethanolamine between about 1:0.2 to about 1:2000. 
     
     
         50 . The dosage unit of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:0.2 to about 1:5. 
     
     
         51 . The dosage unit of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:1 to about 1:50. 
     
     
         52 . The dosage unit of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:15 to about 1:1800. 
     
     
         53 . The dosage unit of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:25 to about 1:450. 
     
     
         54 . The dosage unit of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:50 to about 1:100. 
     
     
         55 . The dosage unit of  claim 49 , wherein the at least one phyto-cannabinoid is tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), a salt thereof, or any combination thereof. 
     
     
         56 . The dosage unit of  claim 55 , wherein the at least one phyto-cannabinoid is THC or a salt thereof. 
     
     
         57 . The dosage unit of  claim 49 , wherein the pharmaceutical composition comprises about 50-1800 mg of N-acylethanolamine or a salt thereof. 
     
     
         58 . The dosage unit of  claim 57 , wherein the pharmaceutical composition comprises about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of N-acylethanolamine or a salt thereof. 
     
     
         59 . The dosage unit of  claim 49 , wherein the at least one N-acylethanolamine is N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof. 
     
     
         60 . The dosage unit of  claim 59 , wherein the N-acylethanolamine is PEA or a salt thereof. 
     
     
         61 . The dosage unit of  claim 49 , wherein the pharmaceutical composition comprises THC or a salt thereof, and PEA or a salt thereof. 
     
     
         62 . The dosage unit of  claim 49 , wherein the pharmaceutical composition comprises about 0.5-10 mg of THC or a salt thereof, and about 200-1800 mg of PEA or a salt thereof. 
     
     
         63 . The dosage unit of  claim 49 , wherein the pharmaceutical composition comprises about 2.5-10 mg of THC or a salt thereof and about 250-1000 mg of PEA or a salt thereof. 
     
     
         64 . The dosage unit of  claim 49 , wherein the pharmaceutical composition comprises about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg of THC or a salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg of PEA or a salt thereof. 
     
     
         65 . The dosage unit of  claim 49 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration. 
     
     
         66 . The dosage unit of  claim 49 , wherein the at least one phyto-cannabinoid comprise THC or a salt thereof and CBD or a salt thereof in a molar ratio between the THC or a salt thereof and CBD or a salt thereof between about 2:1 to about 1:2. 
     
     
         67 . The dosage unit of  claim 49 , wherein the dosage unit is formulated as a powder or gel. 
     
     
         68 . The dosage unit of  claim 49 , wherein the dosage unit is formulated as a spray.